|
Background: fatty liver fatty liver disease (fatty liver disease, FLD) referred to a variety of causes lesions mainly in the liver lobule, triglycerides abnormal accumulation in the liver cells mainly clinicopathologic syndrome In recent years, with the dietary changes in the structure of people's lives, FLD incidence further increased statistics after adjusting for factors such as age, sex and region of residence, fatty liver, alcoholic fatty liver (alcoholic fatty liver disease AFLD) and non-alcoholic fatty liver disease (nonalcoholic fatty liverdisease, NAFLD) the total standard incidence rate of 11.3%, 2.2% and 9.1% (adults and 14.5%, 2.9% and 11.7%), increasingly transcend viral hepatitis, is important cause of liver-related disability and death, has become the medical and social problems of global concern. Fatty liver disease and a variety of factors, it is a result of multi-factor interactions. At present, the role of apoptotic factors in the process of steatosis has attracted the attention of many scholars. Tumor necrosis factor-related apoptosis-inducing ligand (tumor necrosis factor related apoptosisinducing ligand, TRAIL), by Wiley in 1995, discovered and named the human TRAIL gene is located on chromosome 3q26, is composed of five exons encoding 1.77 kb mRNA The molecular weight of 32.5 KDa, and encodes a 281 amino acid residues of the type II transmembrane protein. TRAIL belonging to a member of the TNF superfamily, similar in its structure and other members of this family. TRAIL can be combined with its receptor, induction of apoptosis, or play other biological roles. In recent years through the clinical data and animal studies found that TRAIL expression levels in human peripheral blood lipid levels significantly correlated, and TRAIL can induce hepatic steatosis after infection and alcohol intake, but TRAIL in hepatic steatosis The specific role is unclear. FLD the polymorphism of the incidence of a variety of apoptosis-related factors, TRAIL polymorphism FLD occurrence has not been reported. Objective: through the detection of human peripheral blood TRAIL, transaminases, glucose, lipids, and other biochemical markers and the detection of non-alcoholic fatty liver, alcoholic fatty liver, healthy controls and alcoholics fatty liver divided into four groups TRAIL gene exon 3 ' - non-coding region of the 1525G / A, 1595C / T gene polymorphism, suggesting that the fatty liver of TRAIL and its allele and genotype correlation. Methods: A case-control method, the physical examination crowd with a B-screened 163 patients with fatty liver, which the NAFLD group of 84 cases, AFLD group (79 cases), and at the same time select controls of medical examination for the same period 102 cases, including 80 cases of healthy control subjects. 22 cases of fatty liver alcoholics. Select all objects are fasting detection transaminase, glucose, lipids and other biochemical markers, randomly selected from 44 patients with NAFLD and 35 healthy controls, using enzyme-linked immunosorbent assay (enzyme-linked immunosorbent assay, ELISA) method detects serum soluble TRAIL levels. Exons by polymerase chain reaction - restriction fragment length polymorphism (polymerase chain reaction-Restriction fragment length polymorphism, PCR-RFLP) assay divided into four groups outside TRAIL gene 3'-untranslated region ( the 3'-untranslatedregion 3'-UTR) 1525/1595 two-gene polymorphism. Choose the part of the object through gene sequencing to verify the correctness of the PCR-RFLP method. Results: (1) the amount of non-alcoholic fatty liver serum soluble TRAIL expression was significantly higher than the healthy control group (p = 0.017, p <0.05). (2) serum soluble TRAIL concentration of triglycerides (triglyceride, TG) content was positively correlated (r = 0.368, P = 0.014, P <0.05). (3) the Chinese Han population exists TRAIL gene 1525G / A, 1595C / T mutation. (4) of the 265 officers of the Chinese Han TRAIL gene Fifth outside exon 3'-UTR region 1525,1595 locus polymorphism analysis and found exactly the same individual two-point G / A, C / T gene mutation . (5) NAFLD and AFLD group 1525/1595 genotype distribution compared with the healthy control group with a significant difference (p = 0.016, p <0.05; p = 0.013, p <0.05); 1525/1595 point of NAFLD group G / C allele frequency was significantly higher than the healthy control group (p = 0.017, p <0.05); AFLD group 1525/1595 point G / C allele frequency was significantly higher than the healthy control group (p = 0.022, p <0.05); (6) NAFLD group 1525/1595 point GG / CC genotype TG was significantly higher than the amount of AA / TT genotype TG (p = 0.035, p <0.05); (7) the NAFLD serum propionate leucine aminotransferase (alanine aminotransferase, ALT), aspartate amino transferase (aspartateaminotransferase, AST), gamma-glutamyl GGT (glutamyl transpeptidase, GGT), blood sugar (Blood Glucose, GLU), cholesterol ( cholesterol, CH), TG serum concentrations higher than the healthy control group (no history of drinking) was statistically significant (p <0.05); (8) AFLD group ALT, GLU, CH, TG serum concentrations higher than alcoholics without fatty liver disease group (p <0.05); (9) AFLD group ALT, AST, GGT, GLU, CH, TG levels than the healthy control group (no history of drinking) (p <0.05); (10) non-conditional Logistic regression analysis of the body mass index (body mass index, BMI), waist-to-hip ratio (WHR hipratio, WHR), high blood cholesterol, GGT are risk factors for NAFLD. Conclusion: PCR-RFLP method to detect the TRAIL genotype-specific high mature, stable; Chinese Han population exists TRAIL gene exon 3'-noncoding region 1525G / A, 1595C / T mutation. (1) The study found that patients with NAFLD, serum TRAIL levels and liver steatosis, serum sTRAIL concentration and serum TG levels were positively correlated. (2) Chinese Han population TRAIL gene exon 3'-UTR1525G-1595C allele with fatty liver disease associated genes. (3) The study found that the locus of the 3'-UTR of TRAIL gene exon gene mutation consistent that close to each other tend to be polymorphic loci together genetic, belongs to a haplotype. (4) of TRAIL 1525/1595 sites for GG / CC genotype susceptible to high cholesterol. (5) obesity, high cholesterol, high GGT levels of non-alcoholic fatty liver risk factors.
|